Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer

Genes Chromosomes and Cancer

Volumn 27, Issue 3, 2000, Pages 252-263

  Gildea, John J ^a   Golden, Wendy L ^a   Harding, Michael A ^a   Theodorescu, Dan ^a,b,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CARCINOGENICITY; CONTROLLED STUDY; CYTOGENETICS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; KARYOTYPE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL COUNT; CONTACT INHIBITION; FEMALE; HUMANS; KARYOTYPING; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHENOTYPE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; URINARY BLADDER NEOPLASMS;

ANIMALIA;

EID: 0033956798     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9     Document Type: Article

References (33)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. 1987. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245.
2. Alfthan O, Jauhiainen K, Kaasinen E, Liukkonen T. 1997. Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group. World J Urol 15:89-95.
3. Brewster SF, Gingell JC, Browne S, Brown KW. 1994. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 70:697-700.
4. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. 1973. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 11:765-773.
5. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. 1997. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 14:3059-3066.
6. Flatow U, Rabson AB, Rabson AS. 1987. Tumorigenicity of T24 urinary bladder carcinoma cell sublines. Int J Cancer 40:240-245.
7. Fontana D, Bellina M, Scoffone C, Cagnazzi E, Cappia S, Cavallo F, Russo R, Leonardo E. 1996. Evaluation of c-ras oncogene product (p21)in superficial bladder cancer. Eur Urol 29:470-476.
8. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. 1983. Superficial bladder cancer: progression and recurrence. J Urol 130:1083-1086.
9. Hordijk PL, ten Klooster JP, van der Kammen RA, Michiels F, Oomen LC, Collard JG. 1997. Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. Science 278:1464-1466.
10. Inui M, Nishi N, Yasumoto A, Takenaka I, Miyanaka H, Matsumoto K, Nakamura T, Wada F. 1996. Enhanced gene expression of transforming growth factor-alpha and c-met in rat urinary bladder cancer. Urol Res 24:55-60.
11. Kagan J, Liu J, Stein JD, Wagner SS, Babkowski R, Grossman BH, Katz RL. 1998. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 16:909-913.
12. Kinch MS, Clark GJ, Der CJ, Burridge K. 1995. Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J Cell Biol 130:461-471.
13. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. 1994. Allelotype of human bladder cancer. Cancer Res 54:531-538.
14. Kovnat A, Buick RN, Choo B, De Harven E, Kopelyan I, Trent JM, Tannock IF. 1988. Malignant properties of sublines selected from a human bladder cancer cell line that contains an activated c-Ha-ras oncogene. Cancer Res 48:4993-5000.
15. Landis SH, Murray T, Bolden S, Wingo PA. 1999. Cancer statistics, 1999. CA Cancer J Clin 49:8-32.
16. Li M, Zhang ZF, Reuter VE, Cordon-Cardo C. 1996. Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol 149:229-235.
17. Lipponen P, Eskelinen M. 1994. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69:1120-1125.
18. O'Toole CM, Povey S, Hepburn P, Franks LM. 1983. Identity of some human bladder cancer cell lines. Nature 301:429-430.
19. Polascik TJ, Cairns P, Chang WY, Schoenberg MP, Sidransky D. 1995. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 55:5396-5399.
20. Potempa S, Ridley AJ. 1998. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell 9:2185-2200.
21. Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, Cuthill S. 1996. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 23:571-584.
22. Schmitz-Drager BJ, Jankevicius F, Ackermann R. 1996. Molecular biology of dissemination in bladder cancer - laboratory findings and clinical significance. World J Urol 14:190-196.
23. Schneider BF, Lovell MA, Golden WL. 1998. Cytogenetic abnormalities in primary bronchopulmonary leiomyosarcoma of childhood. Cancer Genet Cytogenet 105:145-151.
24. Senger DR, Perruzzi CA, Ali IU. 1988. T24 human bladder carcinoma cells with activated Ha-ras protooncogene: nontumorigenic cells susceptible to malignant transformation with carcinogen. Proc Natl Acad Sci USA 85:5107-5111.
25. Skinner DG, Stein JP, Lieskovsky G, Skinner EC, Boyd SD, Figueroa A, Jones P, Cote R, Groshen S. 1998. 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 33:25-26.
26. St. Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. 1998. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 142:557-571.
27. Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. 1990. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci USA 87:9047-9051.
28. Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS. 1991. Ha-ras induction of the invasive phenotype results in upregulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res 51:4486-4491.
29. Theodorescu D, Laderoute KR, Calaoagan JM, Gulding KM. 1998a. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not P21ras gene expression. Int J Cancer 78:775-782.
30. Theodorescu D, Laderoute KR, Gulding KM. 1998b. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ 9:919-928.
31. Wagner U, Bubendorf L, Gasser TC, Moch H, Gorog JP, Richter J, Mihatsch MJ, Waldman FM, Sauter G. 1997. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 151:753-759.
32. Wheeless LL, Reeder JE, Han R, MJ OC, Frank IN, Cockett AT, Hopman AH. 1994. Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei. Cytometry 17:319-326.
33. Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz, D, Bierhoff E, Hummerich J, Muller DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A. 1996. Evidence for a novel rumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 12:973-978.